Testosterone drives erythropoiesis through two converging pathways: direct renal erythropoietin stimulation and suppression of hepcidin, which releases iron from macrophage storage and increases bone-marrow iron availability. The resulting rise in red cell mass is the single most consistently tracked adverse biomarker in the TRT and AAS cardiovascular literature.
The reference frame
- Adult male reference range: 40–52% hematocrit.
- Watch zone (TRT/cruise): 52–54%. No immediate action; tighten monitoring cadence.
- Action threshold: >54%. Phlebotomy indicated.
- Hard stop: >58%. Frank polycythaemia with documented stroke, MI, and DVT signal in the cardiovascular outcomes literature.
Plasma viscosity at 58% is approximately double the value at 48%. Shear stress on endothelium scales with viscosity; coagulation cascade activation follows. The risk is not hypothetical — the bodybuilder cardiovascular mortality case series identify erythrocytosis as the single adverse biomarker most consistently present at presentation.
Why it climbs
Testosterone directly stimulates renal EPO release and concurrently suppresses hepcidin expression. Hepcidin normally sequesters iron in macrophages; its suppression releases stored iron for haem synthesis. The result is dose-dependent erythrocytosis — higher testosterone exposure produces steeper rise.
Estradiol counter-regulates. Aggressive AI dosing (E2 crashed below 20 pg/mL) removes the estrogenic brake on erythropoiesis and accelerates HCT rise disproportionately to the testosterone dose. Users running “crushed E2” protocols reliably present with steeper HCT trajectories than users at physiological E2.
The confounder the standard answer omits
Obstructive sleep apnea mimics the testosterone-driven HCT picture. Intermittent nocturnal hypoxia drives EPO release through the same pathway. Users presenting with unexpectedly high HCT despite modest testosterone doses frequently have undiagnosed OSA. Snoring, daytime somnolence, and partner-reported apneic episodes warrant sleep-study workup before attributing the HCT entirely to the protocol.
Management interventions, in order of leverage
Whole-blood donation
450 mL donation drops HCT by approximately 3 percentage points and resets the trajectory for 8–12 weeks. US: every 56 days. EU: every 3 months (male). Document the donation date — phlebotomy protocols depend on interval tracking.
Therapeutic phlebotomy is the medical term when physician-ordered. Mechanism is identical; the documentation pathway changes.
Ferritin surveillance
Repeated phlebotomy depletes iron stores. Ferritin below 30 ng/mL indicates iron-deficiency risk even with HCT still elevated — donating a unit at low ferritin produces fatigue disproportionate to the HCT reduction. Track ferritin alongside CBC every 3rd–4th donation cycle. Target range 50–150 ng/mL.
Dose reduction
20–30% dose reduction lowers HCT over 8–12 weeks. Insufficient as acute intervention at HCT >56%; effective for longer-term management in the 52–54% watch zone.
Low-dose aspirin
81 mg/day as antiplatelet prophylaxis above HCT 52%. The harm-reduction calculus is favourable in high-HCT users without bleeding-risk contraindications. Discuss with a clinician who understands the protocol — gastroprotection may be warranted on chronic use.
Hydration
Not a treatment, a measurement correction. Dehydrated draws read HCT 2–3 percentage points higher than true steady-state. 500 mL water 60 minutes before draw normalises hemoconcentration artefact. Does not affect true polycythaemia.
E2 management
Target sensitive E2 at 25–40 pg/mL. Crushed E2 (<20 pg/mL) removes the estrogenic counter-regulation and accelerates HCT rise. If HCT is climbing faster than expected for the testosterone dose, check E2 before increasing phlebotomy frequency.
Monitoring cadence
CBC every 8–12 weeks on any testosterone protocol. Long-term cruise users: minimum every 3 months. 15–30 EUR for the test at any private lab; the ratio of cost to risk-mitigation is favourable enough that skipping is difficult to justify on any rational protocol-design axis.